About Nanobiotix S.A. (adapted from Nanobiotix S.A. prospectus):
They are a clinical-stage biotechnology company focused on developing first-in-class product candidates that use their proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. Their ordinary shares are listed on the regulated market of Euronext in Paris (“Euronext Paris”) under the symbol “NANO.”

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.